Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Latest Press Releases

Newron to grant safinamide license to Meiji Seika Pharma for Japan and key Asian territories

05/01/2012
English ENG  German GER

Safinamide data to be presented at World Congress on Parkinson's disease and related disorders in Shanghai

13/12/2011
English ENG  German GER

Investor News

Please click here to view Newron share price information on SIX.

take a tour of the brainjobs at newron